Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/52—Juglandaceae (Walnut family)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

• the present invention refers to an isolated extract of walnuts with a high efficiency and stability over time useful for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases.
• the present invention also refers to a process for obtaining said isolated extract of walnuts.
• the walnut extracts and cataplasms have been used during many years in popular dietetic medicaments.
• the walnut tree contains at the bark, leafs or fruits gallic and catequic tannins, juglone, juglandine, carotene, inositol, pyrogallol, vitamin C and other substances .
• Manchurian contains mainly 5-hydroxi-l, 4- naphtoquinones (juglone), 1, 4, 5-trihydroxinaphtalenes
• hydrojuglone glycosides of hydrojuglone, glycosides of hydroxi- ⁇ -tetralone and gallic derivatives of these glycosides. It is also known that the walnut hull is very rich in vitamin C and that betacarotene, Bl, B2 and B6 have been found in the leaves.
• the juglone is considered as a natural product having anti-microbial, anti-neoplastic and anti-parasitic action and has anti-fungal and antiseptic properties. Therefore, it can be found in different market products, including colorant compositions for hair and oil of satin walnuts.
• the juglone, prepared from walnut hull, is an active ingredient active in dietetic complements.
• NCI Cancer Institute
• US 6,296,838, from October 2001 refers to an anti-fungal composition, of topical application, for the treatment and prevention of the human nails infected with fungi.
• the extract with synergic effects contains a mixture of 10-15% of juglone extract from walnut hull with 20-30% of milled roots of Nardostachys jatamansi o Vetiveria zizanioides o Catharanthus roseus, because an extract of only juglone showed very little efficiency even in the long curing treatment and fungi-toxic effect.
• the walnut hulls were separated, washed with water and air dried. Then, they were milled and an extraction of juglone with solvents selected from acetone, alcohol and butanol was carried out. The solvent was removed from the extract and it was cooled to remove the waxes so that the juglone was partially fractionated.
• the isolated extracts of walnuts described in the state of the art are based in the extraction of determined active ingredients with an anti-fungal, antimicrobial or anti-viral purpose, from a part of the tree whose active ingredient is found in great quantities.
• compositions comprising isolated extracts of walnuts present the drawback that it must be administered immediately after its preparation, said compositions having a short life because of the decrease of its effectiveness over time.
• compositions containing them must be produced and administered within few days in order to provide a suitable effectiveness in the treatment .
• compositions based in isolated extracts of walnut have a limited application over time, because of the low stability of the juglone in the extract, and they are exclusively of anti-fungal, antimicrobial or anti-viral type.
• a first aspect of the present invention is, therefore, to provide a walnut-based isolated extract stable over time and independent from the moment it was prepared.
• a second aspect of the present invention is to provide a walnut-based isolated extract which is simultaneously effective in the treatment of fungi, bacteria and virus.
• a third aspect of the invention is to provide a process permitting to obtain an isolated extract of walnuts according to the first and second aspects of the invention .
• a fourth aspect of the present invention is the use of an extract according to the first aspect of the present invention for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases.
• a fifth aspect of the invention is to provide a composition comprising an extract according to the first aspect of the invention to be used in the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases.
• unripe fruits of walnuts is meant that said walnuts are in a Lactic-Waxy ripeness state.
• said ripeness state takes places between 10th of June and 15th of September, more approximately from 10th of July and 10th of August, even though said dates can vary a little according to the weather of the place where the fruit is ripening.
• Fig. 1 shows a flow chart of the process according to the present invention where the obtention of a walnut extract with an extraction time lower than 10 min. is carried out.
• Fig. 2 refers to a graphical representation of the content of juglone in (%) in a walnut extract in respect with the time from its preparation, as a function of the time used during the extraction step. From said Fig. 2 it can be seen that the content of juglone was kept stable over time only when the extraction time is lower than 10 min. (- ⁇ -) .
• the inventors of the present invention have found that the extraction time used during a walnut extract is obtained is a decisive condition in the final properties of the obtained extract.
• the isolated extract of walnuts according to the first aspect of the invention shows properties for a simultaneous anti-fungal, anti-microbial and anti-viral application which is stable over time.
• an isolated extract of walnuts which characterized in that it is obtained from a process comprising: i) Collecting unripe walnut fruits as raw material; ii) Preparing the raw material for the extraction; iii) Freezing the raw material prepared in the previous step; iv) Drying; v) Extracting in a time lower than 10 minutes; vi) Filtration; and vii) Final packaging.
• the preparation of the raw material for the extraction (ii) comprises preferably a mechanical cleaning, a washing with running water, a washing with distilled water and a drying at the air.
• the freezing step (iii) comprises keeping the walnut fruits in a frozen chamber at a temperature comprised between -18 and -20 0 C during 70-170 hours, even more preferably during about 120 ⁇ 5 hours.
• the drying step (iv) comprises, first, peeling the shells of the frozen walnut in thin layers of 2 to 3 mm and, then, place them in trays to leave them dry, preferably under the sun and then in a drying chamber at a temperature of 38°C ⁇ 2°C until a humidity lower than 10% is obtained.
• the extraction step (v) comprises breaking the obtained dried mass, in the drying step, into little pieces, and adding ethyl alcohol (96%) in a 1/2 to 1/5 weight/volume ratio, preferably 1/3, and carrying out an extraction during a time lower than 10 minutes, preferably lower than 5 minutes, even more preferably lower than 2 minutes .
• the filtration step of the extract is carried out preferably in a primary depuration filter and, then, in a bactericide filter of thin pore at a pressure of 0.25 ⁇ 0 . 0 05 MPa .
• the inventors of the present invention have found that the extraction time is critical in the final properties of the isolated extract of walnuts. It is believed that when the extraction time is increased, other components are removed from the walnut that possibly interfere in the stability and efficiency over time of the obtained extract.
• the inventors of the present invention have found that the isolated extract of walnuts obtained according to the first aspect of the invention retains its properties for a simultaneous anti-fungal, anti-microbial and anti-viral application, apart from being stable over time.
• the invention also provides a process for obtaining an isolated extract of walnuts as defined above according to the first aspect of the invention.
• the inventors of the present invention evaluated the stability of the juglone as a function of the time used during the extraction step v) .
• the juglone extract obtained using an extraction time lower than 10 min was kept stable after its preparation during a time up to 24 months and, therefore, its efficiency did not depend on the time from its preparation, but the time used during the extraction time, see assay No. 1 and Fig. 2.
• an extract is obtained with a stability of more than two years, stability substantially longer compared to the walnut extracts disclosed in the state of the art of approximately some days.
• the isolated extract of walnuts according to the present invention has application in the treatment of herpes, chickenpox, fungi on the skin, nails, etc., in general in the treatment of skin diseases.
• the administration of the extract according to the present invention can be carried out by topical, intraperitoneal or oral application such as, e.g. liquid form, creams or tablets, even though other ways of application of the extract according to the present invention are also included in the scope thereof.
• the inventors of the present invention also studied the efficiency of the isolated extract according to the first aspect of the invention in bacteria, fungi and virus of the assays No. 1 to 5 (Table 1) . See Table 2 below.
• an isolated extract of walnuts which is used for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases.
• the invention also refers to a composition comprising an extract according to the first aspect of the invention and to its use for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases.
• the toxicological evaluation of the isolated extract of walnuts according to the first aspect was carried out in rats and mice to which different concentrations of the extract were intragastrically administered.
• the intragastrical administration was proposed in order to obtain a systemic effect on the herpes virus, both in cases of acute infection and in virus carriers.
• the extract can be considered, hence, a natural antiviral chemotherapeutical remedy.
• the manifestation of its toxic properties was expected because it was administered by systemic absorption, which was also confirmed in a sub-acute study with rats and mice. It must be pointed out, however, that the frequency of fatal ends, even when maximum doses are administered intragastrically, is so low that it is impossible to establish average lethal doses (LD 50 , etc.).
• the extract has neither the property of material accumulation nor a mutagenic effect on bone marrow cells.
• About the general toxic properties it is necessary to point out the effect on CNS and the inhibitory action on the growing of the body mass in baby animals.
• the toxicity related to the parenchymatous organs consists of, in particular, the deterioration of the parenchymatous cells of the liver and to the alteration of the excretory function of kidneys.
• the reduction of the spleen and adrenals mass seems to reflect the stress state as a result of the long-term manipulations for 30 days (see table 1.1, ethanol 5%).
• the 50% extract solution produces evident hyperkeratosis, dryness and hardening of the cutaneous folds. Histologically, together with the intensification of the keratinisation process, an increase of the cell layers in the epidermis is also produced, even though in this case no inflammatory effects have been observed. With this dose no systemic toxicity (by absorption) signs have been observed.
• mice received volumes of about 4 times greater than the solutions at the same concentrations (5 and 50% solutions) .
• a granulocytopoietic reaction is also seen, shown in the transformation of the "lymphocytary" type, of hemopoiesis, characteristic of the rodents, to "granulocytary" type.
• the preparation at a concentration of 5% did not produce any destructive or inflammatory change in the mucous membrane of the distal segment of the rectum. At this dose no symptom of a general systemic toxic effect was observed.
• the application on the skin of extract at a extremely high concentration (50%) is accompanied by systemic toxicity effects.
• the characteristic properties of the preparation are also observed, specifically, the stimulation of the keratinisation and the granulocytopoiesis (granulocytosis) with no inflammatory effects on the skin and the mucous membrane .
• mice Taking as a base the determination of the average toxic doses and others in mice (TD 50 - 0.4 ml of solution at 17 ⁇ 3.8 %, TDi 6 - 0.4 ml of solution at 10 %, TD 84 - 0.4 ml of solution at 35% in animals), as an approximate non-toxic dose in conditions of local cutaneous application in rats the dose of 1.0 - 1.5 ml/Kg of 5% solution is taken.
• the extract solutions at a concentration of 5- 50% have neither local irritant nor sensitizing (allergenic) properties when are cutaneously applied.
• the objective of the present study was to examine the isolated extract of walnuts according to the first aspect used in the manufacture of a preparation (hereinafter, the extract) in order to prove the presence of anti-viral activity (anti-herpes) in cell cultures.
• the following cells were used: continue cell line DR of bone sarcoma (obtained from the virology laboratory of the National Centre of Georgia of especially dangerous infections) and primary culture of human fibroblasts of musculocutaneous origin (abortive material, from the Institute of obstetrics, gynaecology and perinatal medicine of the Ministry of Health of Georgia) .
• Viral material - herpes simplex virus type I obtained from the museum of the virology laboratory of the Institute of viral preparations of the Ministry of Health of the Russian Federation (Moscow) .
• the analysis of the obtained results permitted to univocally conclude that the vegetal extract used for the manufacture of the preparation was able to produce the inhibition of the reproduction of the herpes simplex virus in DR cell cultures (bone sarcoma) and musculocutaneous human fibroblasts. This effect was more intense when the extract was used in a dilution of 1:5 (the pure extract was not assayed intentionally taking into account the possibility of a citotoxic effect on the cells) .
• the method of cross valuation of the extract and the virus in cell cultures permitted to demonstrate the protective anti-herpes effect of the extract and to find out some regularities of the course of the infection in the cells.
• the isolated extract of walnuts according to the first aspect demonstrated to have protective properties against to herpes simplex virus (HSV) in cell cultures of human fibroblasts and DR bone sarcoma, so that it was considered necessary to study the anti-viral effect of the extract in white mice.
• HSV herpes simplex virus
• an herpes infection model in white mice was used to study the mortality of the animals and the reproduction index of the virus.
• the state of the immune system of the organism was evaluated in terms of antibody production, phagocytosis and interferon activity.
• the embriotoxic and mutagenic effect of the herpes virus and the state of the antioxidant protection in pregnant females of mouse were also analysed. All these parameters were studied in infected mice treated with the extract.
• the extract produces these effects by means of the active physiological substances contained in it (antibiotic, Juglone and flavonoids; micro-elements; complex of vitamins C, E, PP) , which favour the intensification of the functional activity of the immunocompetent cells. Therefore, the extract can be classified without any doubt among the active natural remedies that can be used efficiently in the prevention and the treatment of viral and bacterial infections, the pyogenic and inflammatory diseases, as well as other pathological states which require an enhancement of the metabolic and adaptive processes.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Biotechnology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Alternative & Traditional Medicine (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=38658587

Family Applications (1)

Country Status (16)

Cited By (3)

Families Citing this family (10)

Citations (1)

Family Cites Families (9)

• 2006
  • 2006-06-02 ES ES200601542A patent/ES2301366B1/es active Active
• 2007
  • 2007-05-29 BR BRPI0711510-5A patent/BRPI0711510A2/pt not_active Application Discontinuation
  • 2007-05-29 JP JP2009512574A patent/JP5319522B2/ja active Active
  • 2007-05-29 CN CN2007800279817A patent/CN101495128B/zh not_active Expired - Fee Related
  • 2007-05-29 AU AU2007255542A patent/AU2007255542B2/en active Active
  • 2007-05-29 ZA ZA200810411A patent/ZA200810411B/xx unknown
  • 2007-05-29 ES ES07729598.8T patent/ES2579181T3/es active Active
  • 2007-05-29 KR KR1020097000061A patent/KR101419799B1/ko active Active
  • 2007-05-29 CA CA2653833A patent/CA2653833C/en active Active
  • 2007-05-29 GE GEAP200711028A patent/GEP20115293B/en unknown
  • 2007-05-29 PL PL07729598.8T patent/PL2040727T3/pl unknown
  • 2007-05-29 EP EP07729598.8A patent/EP2040727B1/en active Active
  • 2007-05-29 WO PCT/EP2007/055176 patent/WO2007141158A2/en not_active Ceased
  • 2007-05-29 UA UAA200815085A patent/UA93915C2/ru unknown
  • 2007-05-29 EA EA200802363A patent/EA015255B1/ru not_active IP Right Cessation
  • 2007-05-29 US US12/302,725 patent/US8206755B2/en active Active
• 2008
  • 2008-11-27 IL IL195586A patent/IL195586A/en active IP Right Grant
• 2012
  • 2012-05-30 US US13/483,639 patent/US8318219B2/en active Active

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events